TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9466468

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTF) 1 mg/kg as a loading dose followed by 1 mg/kg/h
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 12
Study: 7653816

Group type: EXPERIMENTAL
Intervention: Group I: subarachnoid injection of 12 mg hyperbaric tetracaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group II: no spinal injection
Number of subjects: 20
Study: 2496998

Group type: EXPERIMENTAL
Intervention: Cefadroxil
Number of subjects: 239

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 239
Study: 1100300

Group type: EXPERIMENTAL
Intervention: Triazolam, 0.5 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Secobarbital, 100 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29847166

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 331
Study: 28824047

Group type: EXPERIMENTAL
Intervention: Serum osteoglycin levels
Number of subjects: 383

Group type: COMPARATOR
Intervention: Healthy control serum osteoglycin levels
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Osteoglycin levels in diabetic group
Number of subjects: 383
Study: 26329718

Group type: EXPERIMENTAL
Intervention: Silk therapeutic garments plus standard eczema care
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard eczema care alone
Number of subjects: 300
Study: 24282870

Group type: EXPERIMENTAL
Intervention: Oral-B Triumph with SmartGuide (oscillating-rotating brush)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Colgate ProClinical A1500 (sonic brush)
Number of subjects: 130
Study: 22013199

Group type: EXPERIMENTAL
Intervention: Low plasma folate concentrations (lowest quartile)
Number of subjects: 2296

Group type: EXPERIMENTAL
Intervention: High plasma tHcy concentration
Number of subjects: 2296

Group type: EXPERIMENTAL
Intervention: Plasma cobalamin concentration
Number of subjects: 2296
Study: 18433528

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy at 1.4 ATA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy at 1.5 ATA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy at 1.6 ATA
Number of subjects: 60
Study: 16487219

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 or 40 mg daily for 24 weeks
Number of subjects: 0
Study: 14660810

Group type: EXPERIMENTAL
Intervention: Chinese herbal drug formula (n=33)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (n=32)
Number of subjects: 65
Study: 11464183

Group type: EXPERIMENTAL
Intervention: Docosanol 10% cream
Number of subjects: 737

Group type: COMPARATOR
Intervention: Placebo (polyethylene glycol)
Number of subjects: 737
Study: 9605367

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg orally
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Morphine 10 mg intramuscularly
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 7999289

Group type: EXPERIMENTAL
Intervention: Oral-B Advantage Plaque Remover
Number of subjects: 230
Study: 3377059

Group type: EXPERIMENTAL
Intervention: 38% water content hydrogel lenses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 67% water content hydrogel lenses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Altered lens parameters (fitting characteristics)
Number of subjects: 0
Study: 31383564

Group type: EXPERIMENTAL
Intervention: Patient Therapeutic Education (PTE) combined with spa therapy
Number of subjects: 340

Group type: COMPARATOR
Intervention: Spa therapy alone (control group)
Number of subjects: 340
Study: 28258537

Group type: EXPERIMENTAL
Intervention: SCRIPT online educational module
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 24196463

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia with 0.2% ropivacaine, ketorolac, and adrenaline followed by continuous infusion of 0.2% ropivacaine at 5 mL/hr
Number of subjects: 105

Group type: COMPARATOR
Intervention: Local infiltration analgesia with 0.2% ropivacaine, ketorolac, and adrenaline followed by continuous infusion of saline solution at 5 mL/hr
Number of subjects: 105

Group type: COMPARATOR
Intervention: Local infiltration with saline solution followed by continuous infusion of saline solution at 5 mL/hr
Number of subjects: 105
Study: 21689412

Group type: EXPERIMENTAL
Intervention: Proactive strategy using periodic e-mail prompts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reactive strategy
Number of subjects: 0
Study: 19589264

Group type: EXPERIMENTAL
Intervention: Mitiglinide 10-20 mg three times daily
Number of subjects: 291

Group type: COMPARATOR
Intervention: Nateglinide 120 mg three times daily
Number of subjects: 291
Study: 16485228

Group type: EXPERIMENTAL
Intervention: Covered sclerotomy (ST)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Covered sclerotomy with viscoelastic filling (ST+H)
Number of subjects: 58
Study: 14769679

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - nurse-managed cognitive behavioral relapse-prevention intervention at bedside, with telephone contact after discharge
Number of subjects: 277

Group type: COMPARATOR
Intervention: Usual-Care Group (UG) - strong physician's advice, a self-help pamphlet, and a list of community resources
Number of subjects: 277
Study: 11755327

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (5 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural S(+)‐ketamine (0.1 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural S(+)‐ketamine (0.2 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (epidural saline and transdermal placebo)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nitroglycerin/0.1 mg/kg S(+)‐ketamine (1 NKG)
Number of subjects: 60
Study: 9686072

Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 29334615

Group type: EXPERIMENTAL
Intervention: Self-paced graded exercise testing (SPV)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ramp graded exercise testing (RAMP)
Number of subjects: 16
Study: 26465374

Group type: EXPERIMENTAL
Intervention: Novolimus-eluting stent (NES), n=139
Number of subjects: 210

Group type: COMPARATOR
Intervention: Zotarolimus-eluting stent (ZES), n=71
Number of subjects: 210
Study: 24955623

Group type: EXPERIMENTAL
Intervention: Technical Skill Assessment Instrument (TSAI)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Decision study projections
Number of subjects: 29
Study: 22890436

Group type: EXPERIMENTAL
Intervention: Closed kinetic chain (CKC) exercises at 15 degrees of flexion
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Open kinetic chain (OKC) exercises at 30 degrees of flexion
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Closed kinetic chain (CKC) exercises at 30 degrees of flexion
Number of subjects: 39
Study: 19846891

Group type: EXPERIMENTAL
Intervention: Cephalic stimulation
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sham feeding
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Gastric retention
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Duodenal instillation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (normal ingestion)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Inflated intrapyloric balloon during satiety testing
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Deflated intrapyloric balloon during satiety testing
Number of subjects: 11
Study: 16417534

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 1000 mg twice daily
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 15159248

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Purified trans‐10,cis‐12 isomer of CLA
Number of subjects: 0
Study: 11561046

Group type: EXPERIMENTAL
Intervention: High frequency repetitive transcranial magnetic stimulation (HF‐rTMS) applied to the left dorsolateral prefrontal area in daily sessions for 10 consecutive working days.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham HF‐rTMS
Number of subjects: 28
Study: 9783947

Group type: EXPERIMENTAL
Intervention: Epidural and/or general anesthesia
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 110
Study: 8162718

Group type: EXPERIMENTAL
Intervention: Propafenone, 150 mg every 4 h
Number of subjects: 50

Group type: COMPARATOR
Intervention: Verapamil, 40 mg every 4 h
Number of subjects: 50
Study: 2832763

Group type: COMPARATOR
Intervention: Radiation only (2,100 cGy in seven fractions)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Radiation plus iv chemotherapy (5-fluorouracil)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Radiation plus intra-arterial chemotherapy (5-fluorouracil)
Number of subjects: 166
Study: 30777890

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 1412
Study: 28433557

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control
Number of subjects: 73
Study: 26678294

Group type: EXPERIMENTAL
Intervention: PCHMS (Personally Controlled Health Management System)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (online static educational content)
Number of subjects: 330
Study: 23741444

Group type: EXPERIMENTAL
Intervention: Noise-based tube current with filtered back projection (Group 2, n=109)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Noise-based tube current with iterative reconstruction (Group 3, n=116)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Iterative reconstruction (Group 3)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Fixed tube current with filtered back projection (Group 1, n=113)
Number of subjects: 338
Study: 21391876

Group type: EXPERIMENTAL
Intervention: Immediate cord clamping (ICC) at 5-10 s
Number of subjects: 42

Group type: COMPARATOR
Intervention: Delayed cord clamping (DCC) at 30-45 s
Number of subjects: 42
Study: 18498540

Group type: EXPERIMENTAL
Intervention: Rectal challenge with cow's milk protein (CM)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CM-sensitive patients
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CM-free diet
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study: 16729787

Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray, 64 microg (32 microg per nostril) once daily for 1 year
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo for 1 year
Number of subjects: 229
Study: 15047457

Group type: EXPERIMENTAL
Intervention: Docetaxel and estramustine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mitoxantrone
Number of subjects: 0
Study: 11335776

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 9383177

Group type: EXPERIMENTAL
Intervention: Hypertonic NaCl solution (100 mmol NaCl in 50 ml) administered to untreated hypertensives
Number of subjects: 33

Group type: COMPARATOR
Intervention: Antihypertensive treatment (single drug or combination) for 1 month
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Hypertonic saline after lowering arterial pressure
Number of subjects: 33

Group type: COMPARATOR
Intervention: Clonidine (0.3 mg in 100 ml)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sodium nitroprusside (50 mg in 250 ml)
Number of subjects: 33
Study: 8281243

Group type: EXPERIMENTAL
Intervention: Fluoxetine (80 mg/day)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Imipramine (200 mg/day)
Number of subjects: 118
Study: 3318432

Group type: EXPERIMENTAL
Intervention: Nabumetone 1,000 mg once daily at bedtime
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 31955321

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study: 30738555

Group type: EXPERIMENTAL
Intervention: Lithium treatment for 28 weeks (n = 17)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo treatment for 28 weeks (n = 14)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 31
Study: 28042985

Group type: EXPERIMENTAL
Intervention: Routine annual health examination with functional evaluations, exercise instruction, and nutrition education
Number of subjects: 404

Group type: COMPARATOR
Intervention: Routine annual health examination
Number of subjects: 404
Study: 26319476

Group type: EXPERIMENTAL
Intervention: Endovenous Laser Ablation (EVLA)
Number of subjects: 400

Group type: COMPARATOR
Intervention: High Ligation and Stripping (HLS)
Number of subjects: 400
Study: 24084768

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 503

Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 503
Study: 21725257

Group type: EXPERIMENTAL
Intervention: Novel Baha implant system
Number of subjects: 77

Group type: COMPARATOR
Intervention: Previous-generation implant system
Number of subjects: 77
Study: 19905916

Group type: EXPERIMENTAL
Intervention: Education with self-management plan (ESM)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Education without self-management plan (E)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both E and ESM groups
Number of subjects: 88
Study: 16686572

Group type: EXPERIMENTAL
Intervention: Weight training at 60% of 1 repetition maximum (1RM) with repetitions to exhaustion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight training at 80% of 1 repetition maximum (1RM) with limited repetitions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood lactate measurements included in total energy expenditure interpretation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxygen uptake-only measurements
Number of subjects: 0
Study: 15016033

Group type: EXPERIMENTAL
Intervention: Electric powered toothbrush
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional manual toothbrush
Number of subjects: 24
Study: 11318767

Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg once daily in the morning
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg once daily in the evening
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg twice daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg twice daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 9129752

Group type: EXPERIMENTAL
Intervention: Daily oxymetazoline (b.i.d. 150 microliters per nostril)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intermittent oxymetazoline (substituted for vehicle on days 1, 3, and 7)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Daily vehicle (b.i.d. 150 microliters per nostril)
Number of subjects: 50
Study: 7962364

Group type: EXPERIMENTAL
Intervention: Mental imagery instructions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Verbal labeling training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Learning instructions (imagery or verbal labeling)
Number of subjects: 60
Study: 3503965

Group type: EXPERIMENTAL
Intervention: Serum physiologic therapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Amoxicillin + antihistaminic + nose drops therapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Amoxicillin clavulanate + antihistaminic + nose drops therapy
Number of subjects: 80
Study: 29949052

Group type: EXPERIMENTAL
Intervention: In-class education
Number of subjects: 50

Group type: COMPARATOR
Intervention: Online education
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Standardized patient willingness
Number of subjects: 50
Study: 28259894

Group type: EXPERIMENTAL
Intervention: Night-shift work (NSW)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Habitual sleep
Number of subjects: 53
Study: 26028917

Group type: EXPERIMENTAL
Intervention: Tacrolimus and sirolimus
Number of subjects: 28

Group type: COMPARATOR
Intervention: Tacrolimus and mycophenolate mofetil
Number of subjects: 28
Study: 24684813

Group type: EXPERIMENTAL
Intervention: Lokomat training
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (fifteen iSCI patients)
Number of subjects: 15
Study: 22810444

Group type: EXPERIMENTAL
Intervention: Bayesian adaptive designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Examples of design adaptations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Designs suitable for exploratory trials, explanatory trials, and trials assessing cost‐effectiveness
Number of subjects: 0
Study: 19108001

Group type: EXPERIMENTAL
Intervention: SG 100
Number of subjects: 56

Group type: COMPARATOR
Intervention: ePTFE
Number of subjects: 56
Study: 17317400

Group type: EXPERIMENTAL
Intervention: Optec 800 visual acuity device
Number of subjects: 33

Group type: COMPARATOR
Intervention: ETDRS chart
Number of subjects: 33
Study: 15352917

Group type: EXPERIMENTAL
Intervention: Effervescent ranitidine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Almagate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12785672

Group type: EXPERIMENTAL
Intervention: Qualitative feedback (verbal encouragement)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Quantitative feedback (algebraic error score)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Combination of Qualitative and Quantitative feedback
Number of subjects: 77

Group type: COMPARATOR
Intervention: No feedback (Control)
Number of subjects: 77
Study: 9830255

Group type: EXPERIMENTAL
Intervention: Quadriplegic spinal cord injury (SCI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paraplegic spinal cord injury (SCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls (traumatic injuries other than SCI)
Number of subjects: 0
Study: 8083767

Group type: EXPERIMENTAL
Intervention: 5% propolis in aqueous alcohol solution
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 5% aqueous alcohol
Number of subjects: 27

Group type: COMPARATOR
Intervention: No mouth rinse
Number of subjects: 27
Study: 2520406

Group type: EXPERIMENTAL
Intervention: Guanethidine (20 mg in 50 ml 0.5% lidocaine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Reserpine (1.25 mg in 50 ml 0.5% lidocaine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (50 ml 0.5% lidocaine)
Number of subjects: 12
Study: 268710

Group type: EXPERIMENTAL
Intervention: Fiomed II (coloured, stabilized with SO2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Histoacryl blue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fiomed III (coloured, without SO2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fiomed I (without dye, stabilized with SO2)
Number of subjects: 0
Study: 31562608

Group type: EXPERIMENTAL
Intervention: Trelagliptin 100 mg once weekly
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg once daily
Number of subjects: 27
Study: 28619476

Group type: EXPERIMENTAL
Intervention: Brexanolone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 26010524

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Patient Education (ED)
Number of subjects: 103
Study: 23489465

Group type: EXPERIMENTAL
Intervention: Artesunate (100 mg)/lumefantrine (480 mg) (ASLF FDC)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Artemether (80 mg)/lumefantrine (480 mg) (AMLF FDC)
Number of subjects: 158
Study: 20955637

Group type: EXPERIMENTAL
Intervention: Topical application of mitomycin C after surgical shave excision
Number of subjects: 20
Study: 19344196

Group type: EXPERIMENTAL
Intervention: Finger-tip testing (FT)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Forearm alternative site testing (AST)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 174
Study: 16705054

Group type: EXPERIMENTAL
Intervention: Insulin infusion at low dose (LD, 0.05 mUxmin(‐1)x100 ml(‐1))
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Insulin infusion at intermediate dose (ID, 0.15 mUxmin(‐1)x100 ml(‐1))
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Insulin infusion at high dose (HD, 0.30 mUxmin(‐1)x100 ml(‐1))
Number of subjects: 19
Study: 14744846

Group type: EXPERIMENTAL
Intervention: HI-CHO diet (18% fat, 19% protein, 63% carbohydrates, 26 g of fiber per 1000 kcal)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: HI-CHO + EX diet (HI-CHO diet plus endurance exercise 4 d/wk, 45 min/d, at 80% peak oxygen consumption)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control diet (41% fat, 14% protein, 45% carbohydrates, and 7 g of fiber per 1000 kcal)
Number of subjects: 34
Study: 11525551

Group type: EXPERIMENTAL
Intervention: Dicon
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: EyeSys
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Keratron
Number of subjects: 9
Study: 12017933

Group type: EXPERIMENTAL
Intervention: Arm & Hammer PeroxiCare (52% baking soda, 3% sodium percarbonate)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Arm & Hammer Dental Care (65% baking soda)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Microbiological analysis from a 50-subject subset
Number of subjects: 101
Study: 8505833

Group type: EXPERIMENTAL
Intervention: Weighted enteral feeding tubes
Number of subjects: 39

Group type: COMPARATOR
Intervention: Unweighted enteral feeding tubes
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg in adults, 0.1 mg/kg in children) with unweighted tube
Number of subjects: 39
Study: 3710499

Group type: EXPERIMENTAL
Intervention: 20 g of activated charcoal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 0
Study: 30128932

Group type: EXPERIMENTAL
Intervention: Demographic and social-cognitive factors (intention, self-efficacy, outcome expectancies, social support, motivation)
Number of subjects: 1973

Group type: EXPERIMENTAL
Intervention: Supportive environment (family and friends avoiding discouragement for healthy eating)
Number of subjects: 1973
Study: 26329396

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 432

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432